Effect of the novel antipsychotic drug perospirone on P-glycoprotein function and expression in Caco-2 cells

European Journal of Clinical Pharmacology

Volumn 64, Issue 7, 2008, Pages 697-703

  Zhou, Yan Gang ^a   Li, Kun Yan ^b   Li, Huan De ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b HUNAN CANCER HOSPITAL   (China)

Author keywords

Caco 2 cells; MDR1; P glycoprotein; Perospirone; Rhodamine 123 assay

Indexed keywords

GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PEROSPIRONE; RHODAMINE 123; VERAPAMIL;

ARTICLE; CELL STRAIN CACO 2; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIPSYCHOTIC AGENTS; BASE SEQUENCE; CACO-2 CELLS; CELL LINE, TUMOR; DNA PRIMERS; HUMANS; ISOINDOLES; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHODAMINE 123; RNA, MESSENGER; THIAZOLES;

EID: 44449121844     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0487-5     Document Type: Article

References (40)

1. Fromm MF (2004) Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25:423-429
2. Martin E, Uhr M (2006) ABC drug transporter at the blood-brain barrier: effects on drug metabolism and drug response. Eur Arch Psychiatry Clin Neurosci 256:294-298
3. Schinkel AH (1999) P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev 36:179-194
4. Loscher W, Potschka H (2005) Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76:22-76
5. Tellingen OV (2001) The importance of drug-transporting P-glycoproteins in toxicology. Toxicol Lett 120:31-41
6. Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B (2003) The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett 140-141:133-143
7. Mueser KT, McGurk SR (2004) Schizophrenia. Lancet 363:2063-2072
8. Tandon R, Fleischhacker WW (2005) Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res 79:145-155
9. El Ela AA, Hartter S, Schmitt U, Hiemke C, Spahn-Langguth H, Langguth P (2004) Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds-implications for pharmacokinetics of selected substrates. J Pharm Pharmacol 56:967-975
10. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW (2002) Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marked drugs. J Pharmacol Exp Ther 303:1029-1037
11. Onrust SV, McClellan K (2001) Perospirone. CNS Drugs 15:329-337
12. De Paulis T (2002) Perospirone (Sumitomo Pharmaceuticals). Curr Opin Invest Drugs 3:121-129
13. Hanelt M, Gareis M, Kollarczik B (1994) Cytotoxicity of mycotoxin evaluated by the MTT cell-culture assay. Mycopathologia 128:167-174
14. Aouali N, Eddabra L, Macadré J, Morjani H (2005) Immunosuppressors and reversion of multidrug-resistance. Crit Rev Oncol Hematol 56:61-70
15. Ejsing TB, Pedersen AD, Linnet K (2005) P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments. Hum Psychopharmacol Clin Exp 20:493-500
16. Araki T, Kasai K, Rogers MA, Kato N, Iwanami A (2006) The effect of perospirone on auditory P300 in schizophrenia: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 30:1083-1090
17. Araki T, Yamasue H, Sumiyoshi T, Kuwabara H, Suga M, Iwanami A, Kato N, Kasai K (2006) Perospirone in the treatment of schizophrenia: effect on verbal memory organization. Prog Neuropsychopharmacol Biol Psychiatry 30:204-208
18. Yoshino T, Nisijima K, Shioda K, Yui K, Katoh S (2004) Perospirone, a novel atypical antipsychotic drug, potentiates fluoxetine-induced increase in dopamine levels via multireceptor actions in the rat medial prefrontal cortex. Neurosci Lett 364:16-21
19. Shimakura J, Tani N, Mizuno Y, Komuro S, Kanamaru H (2003) In vitro drug-drug interactions with perospirone and concomitantly administered drugs in human liver microsomes. Eur J Drug Metab Pharmacokinet 28:67-72
20. Kitamura A, Mizuno Y, Natsui K, Yabuki M, Komuro S, Kanamaru H (2005) Characterization of human cytochrome P450 enzymes involved in the in vitro metabolism of perospirone. Biopharm Drug Dispos 26:59-65
21. Mizuno Y, Tani N, Komuro S, Kanamaru H, Nakatsuka I (2003) In vitro metabolism of perospirone in rat, monkey and human liver microsomes. Eur J Drug Metab Pharmacokinet 28:59-65
22. 2 receptor occupancy in the living human brain. J Clin Psychopharmacol 26:531-533
23. Yasui-Furukori N, Furukori H, Nakagami T, Saito M, Inoue Y, Kaneko S, Tateishi T (2004) Steady-state Pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit 26:361-365
24. Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR (2007) Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 46:359-388
25. Gerlach M, Hünnerkopf R, Rothenhöfer S, Libal G, Burger R, Clement HW, Fegert JM, Wewetzer Ch, Mehler-Wex C (2007) Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. Pharmacopsychiatry 40:72-76
26. Hiemke C, Dragicevic A, Gründer G, Hatter S, Sachse J, Vernaleken I, Muller MJ (2004) Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 26:156-160
27. Szabó D, Szabó G Jr, Ocsovszki I, Aszalos A, Molnár J (1999) Anti-psychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex-vivo. Cancer Lett 139:115-119
28. Wang RB, Kuo CL, Lien LL, Lien EJ (2003) Structure-activity relationship: analyses of p-glycoprotein substrates and inhibitors. J Clin Pharm Ther 28:203-228
29. Jin S, Gorfajn B, Faircloth G, Scotto KW (2000) Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci USA 97:6775-6779
30. Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV, Limtrakul PN (2002) Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 64:573-582
31. Yu ST, Chen TM, Tseng SY, Chen YH (2007) Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells. Biochem Biophys Res Commun 358:79-84
32. Mutoh K, Tsukahara S, Mitsuhashi J, Katayama K, Sugimoto Y (2006) Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells. Cancer Sci 97:1198-1204
33. Kanzaki A, Takebayashi Y, Ren XQ, Miyashita H, Mori S, Akiyama S, Pommier Y (2002) Overcoming multidrug drug resistance in P-glycoprotein/MDR1- overexpressing cell lines by ecteinascidin 743. Mol Cancer Ther 1:1327-1334
34. Jetté L, Beaulieu E, Leclerc JM, Béliveau R (1996) Cyclosporin A treatment induces overexpression of P-glycoprotein in the kidney and other tissues. Am J Physiol 270:F756-F765
35. Herzog CE, Tsokos M, Bates SE, Fojo AT (1993) Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists. J Biol Chem 268:2946-2952
36. Keks NA, Altson K, Hope J, Krapivensky N, Culhane C, Tanaghow A, Doherty P, Bootle A (1999) Use of antipsychotics and adjunctive medications by an inner urban community psychiatric service. Aust N Z J Psychiatry 33:896-901
37. Boulton DW, DeVane CL, Liston HL, Markowitz JS (2002) In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 71:163-169
38. Bettencourt MV, Bosne-David S, Amaral L (2000) Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis. Int J Antimicrob Agents 16:69-71
39. Wang JS, Zhu HJ, Markowitz JS, Donovan JL, DeVane CL (2006) Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl) 187:415-423
40. Masui T, Kusumi I, Takahashi Y, Koyama T (2005) Efficacy of carbamazepine against neuroleptic-induced akathisia in treatment with perospirone: case series. Prog Neuropsychopharmacol Biol Psychiatry 29:343-346